| 发明名称 |
3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 摘要 |
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. |
| 申请公布号 |
US2014341991(A1) |
申请公布日期 |
2014.11.20 |
| 申请号 |
US201414450569 |
申请日期 |
2014.08.04 |
| 申请人 |
GlaxoSmithKline LLC |
发明人 |
KAPSI Shivakumar;Muller Francis X. |
| 分类号 |
A61K31/4152;A61K9/20 |
主分类号 |
A61K31/4152 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. The pharmaceutical tablet comprising:
a) a drug, which is 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine); wherein, b) 90% of the drug particles have a particle size greater than 10 micron but less than 90 micron. |
| 地址 |
Wilmington DE US |
